Business litigation partner Claire Schenk recently authored an article on the Federal Priority Act for The Federal Lawyer, the magazine of the Federal Bar Association.
The article, “Addressing the language and scope of the Federal Priority Act,” studies the past, present, and future reach of the Federal Priority Act, a law that allows the federal government’s claims against a debtor to take priority over any other claims.
The statute dates back centuries, but is little-known among today’s practitioners, which is problematic, particularly since the FPA may impose personal liability upon representatives of the person making the improper payment, e.g., corporate officers and directors. Since 2011, the government has used the FPA to recover significant sums from all types of insolvent businesses and individuals — manufacturers, insurance companies, shareholders of a tech company, government contractors, even an individual attorney.
“Different government agencies have invoked the FPA fairly actively in recent years,” Claire writes. “Since the end of 2011, the Act has been cited in approximately 15 cases. Of these cases, the most common circumstances involved claims against insolvent government debtors arising from unpaid estate taxes. The common facts tended to involve an executor of an estate who distributed an estate’s funds before paying debts owed to the federal government, and consequently left the estate with insufficient funds to fully discharge its debt to the federal government.”
This article gives an overview of the FPA, the types of cases where FPA claims crop up, successful defenses against the Act, and the surprisingly expansive breadth the law has enjoyed before federal and appellate courts.
Claire concentrates her practice in the areas of Health Care Fraud and Abuse, False Claims Act litigation and other complex white-collar civil litigation. Drawing upon her 14-year history with the Department of Justice and service as a Civil Chief, Claire represents and advises health care providers, registrants under the Controlled Substances Act and government contractors. She frequently guides physician groups, hospitals, pharmaceutical groups and others through the maze of complex and overlapping government regulatory schemes and assisting with the resolution of compliance concerns.
Although we would like to hear from you, we cannot represent you until we know that doing so will not create a conflict of interest. Also, we cannot treat unsolicited information as confidential. Accordingly, please do not send us any information about any matter that may involve you until you receive a written statement from us that we represent you (an ‘engagement letter’).
By clicking the ‘ACCEPT’ button, you agree that we may review any information you transmit to us. You recognize that our review of your information, even if you submitted it in a good faith effort to retain us, and, further, even if you consider it confidential, does not preclude us from representing another client directly adverse to you, even in a matter where that information could and will be used against you. Please click the ‘ACCEPT’ button if you understand and accept the foregoing statement and wish to proceed.